{
    "ticker": "BMRN",
    "name": "BioMarin Pharmaceutical Inc.",
    "description": "BioMarin Pharmaceutical Inc. is a global biotechnology company focused on developing and commercializing innovative biopharmaceuticals for serious diseases and medical conditions. Founded in 1997 and headquartered in San Rafael, California, BioMarin specializes in treatments for rare genetic disorders. The company's portfolio includes therapeutics that target conditions such as phenylketonuria (PKU), achondroplasia, and various lysosomal storage disorders. BioMarin is committed to advancing the science of enzyme replacement therapies and gene therapy, with several of its products receiving orphan drug designation to expedite their development. Their flagship products, such as Vimizim and Kengreal, have significantly impacted patient lives by providing effective treatment options for previously unmet medical needs. The company invests heavily in research and development, with a robust pipeline of therapies that aim to address a range of genetic disorders. BioMarin's mission is to transform the treatment of rare diseases and to make a meaningful difference in the lives of patients and families affected by these conditions.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Rafael, California, USA",
    "founded": "1997",
    "website": "https://www.biomarin.com",
    "ceo": "Jean-Jacques Bienaim\u00e9",
    "social_media": {
        "twitter": "https://twitter.com/BioMarin",
        "linkedin": "https://www.linkedin.com/company/biomarin-pharmaceutical-inc/"
    },
    "investor_relations": "https://investors.biomarin.com",
    "key_executives": [
        {
            "name": "Jean-Jacques Bienaim\u00e9",
            "position": "CEO"
        },
        {
            "name": "Henry Fuchs",
            "position": "President of Worldwide Research and Development"
        }
    ],
    "product_categories": [
        {
            "category": "Enzyme Replacement Therapies",
            "products": [
                "Vimizim",
                "Naglazyme"
            ]
        },
        {
            "category": "Gene Therapies",
            "products": [
                "Roctavian"
            ]
        }
    ],
    "seo": {
        "meta_title": "BioMarin Pharmaceutical Inc. | Innovative Biopharmaceuticals for Rare Diseases",
        "meta_description": "Explore BioMarin Pharmaceutical Inc., a leader in biotechnology focused on developing innovative therapies for rare genetic disorders. Learn about their groundbreaking products and commitment to patients.",
        "keywords": [
            "BioMarin",
            "Biotechnology",
            "Pharmaceuticals",
            "Rare Diseases",
            "Enzyme Replacement Therapy",
            "Gene Therapy"
        ]
    },
    "faq": [
        {
            "question": "What is BioMarin known for?",
            "answer": "BioMarin is known for developing innovative therapies for rare genetic disorders."
        },
        {
            "question": "Who is the CEO of BioMarin?",
            "answer": "Jean-Jacques Bienaim\u00e9 is the CEO of BioMarin Pharmaceutical Inc."
        },
        {
            "question": "Where is BioMarin headquartered?",
            "answer": "BioMarin is headquartered in San Rafael, California, USA."
        },
        {
            "question": "What are BioMarin's main products?",
            "answer": "BioMarin's main products include Vimizim, Naglazyme, and Roctavian."
        },
        {
            "question": "When was BioMarin founded?",
            "answer": "BioMarin was founded in 1997."
        }
    ],
    "competitors": [
        "VRTX",
        "ALNY",
        "SGEN",
        "RHHBY"
    ],
    "related_stocks": [
        "GILD",
        "AMGN",
        "BMY",
        "REGN"
    ]
}